Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats.
Neuropathy and encephalopathy represent important complications of diabetes. Recent observations obtained in experimental models have suggested that, in male rats, neuroactive steroids are protective agents and that their levels in peripheral (PNS) and central (CNS) nervous system are strongly affected by the disease. It is interesting to highlight that incidence, progression and severity of diabetic neuropathy and diabetic encephalopathy are different in the two sexes. Consequently, it is important to determine the changes in neuroactive steroid levels in the PNS and the CNS of both males and females. To this aim, we have evaluated the levels of neuroactive steroids such as, pregnenolone, progesterone and its metabolites, testosterone and its metabolites, and dehydroepiandrosterone in different CNS regions (i.e., cerebral cortex, cerebellum and spinal cord) and in the sciatic nerve of control and diabetic (i.e., induced by streptozotocin) male and female rats. Data obtained by liquid chromatography-tandem mass spectrometry indicate that the levels of neuroactive steroids show sex and regional differences in control animals. Streptozotocin-induced diabetes resulted in a strong general decrease in neuroactive steroid levels, in both the PNS and the CNS. In addition, the effects of diabetes on neuroactive steroid levels also show sex and regional differences. These findings may have strong implications for the development of new sex-oriented therapies for the treatment of diabetic neuropathy and diabetic encephalopathy, based on the use of neuroactive steroids.
Pesaresi
Marzia
M
Department of Endocrinology, Pathophysiology, and Applied Biology - Center of Excellence on Neurodegenerative Diseases, University of Milan, Milano, Italy.
Maschi
Omar
O
Giatti
Silvia
S
Garcia-Segura
Luis Miguel
LM
Caruso
Donatella
D
Melcangi
Roberto Cosimo
RC
D000818:Animals; D001921:Brain / Q000378:metabolism / Q000473:pathology; D001927:Brain Diseases / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D016022:Case-Control Studies; D003687:Dehydroepiandrosterone / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism* / Q000473:pathology; D003929:Diabetic Neuropathies / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D030762:Estrous Cycle / Q000378:metabolism; D005260:Female; D012739:Gonadal Steroid Hormones / Q000378:metabolism*; D008297:Male; D018696:Neuroprotective Agents / Q000378:metabolism*; D017933:Peripheral Nervous System / Q000378:metabolism / Q000473:pathology; D011284:Pregnenolone / Q000378:metabolism; D011374:Progesterone / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012727:Sex Characteristics; D012737:Sex Factors; D013116:Spinal Cord / Q000378:metabolism / Q000473:pathology; D013739:Testosterone / Q000378:metabolism
D012739:Gonadal Steroid Hormones; D018696:Neuroprotective Agents; D013739:Testosterone; D003687:Dehydroepiandrosterone; D011374:Progesterone; D011284:Pregnenolone